Trastuzumab has been approved for use in the adjuvant setting in the United States for women with node-positive, HER2-overexpressing breast cancer as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. The gene discussed is ERBB2; the disease is breast cancer.